Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Anastrozole-Induced Carpal Tunnel Syndrome
- Guidelines for the Use of Antiemetics in Clinical Oncology
- Association of Stromal Tumor–Infiltrating Lymphocytes With Recurrence-Free Survival in Early-Stage HER2-Positive Breast Cancer
- Accelerated Partial Breast Irradiation Is Noninferior to Whole Breast Irradiation
- Etirinotecan Pegol vs Treatment of Physician's Choice for Previously Treated Advanced Breast Cancer
- Prevention of Chemotherapy-Induced Nausea With Fosaprepitant
- Comparison of Dabrafenib and Trametinib Combination Therapy With Vemurafenib Monotherapy on Health-Related Quality of Life in Patients With Unresectable or Metastatic Cutaneous BRAF Val600 Mutation–Positive Melanoma
- Genetic Differences Between Primary Breast Cancer Among Black and White Women
- ECC 2015: Recommendations From Dr. Lee Schwartzberg
- Breast Cancer Mortality and Ductal Carcinoma In Situ